129 results about "Staphylococcus saprophyticus" patented technology

The present invention relates to DNA-based methods for universal bacterial detection, for specific detection of the common bacterial pathogens Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Staphylococcus saprophyticus, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis as well as for specific detection of commonly encountered and clinically relevant bacterial antibiotic resistance genes directly from clinical specimens or, alternatively, from a bacterial colony. The above bacterial species can account for as much as 80% of bacterial pathogens isolated in routine microbiology laboratories. The core of this invention consists primarily of the DNA sequences from all species-specific genomic DNA fragments selected by hybridization from genomic libraries or, alternatively, selected from data banks as well as any oligonucleotide sequences derived from these sequences which can be used as probes or amplification primers for PCR or any other nucleic acid amplification methods. This invention also includes DNA sequences from the selected clinically relevant antibiotic resistance genes. With these methods, bacteria can be detected (universal primers and/or probes) and identified (species-specific primers and/or probes) directly from the clinical specimens or from an isolated bacterial colony. Bacteria are further evaluated for their putative susceptibility to antibiotics by resistance gene detection (antibiotic resistance gene specific primers and/or probes). Diagnostic kits for the detection of the presence, for the bacterial identification of the above-mentioned bacterial species and for the detection of antibiotic resistance genes are also claimed. These kits for the rapid (one hour or less) and accurate diagnosis of bacterial infections and antibiotic resistance will gradually replace conventional methods currently used in clinical microbiology laboratories for routine diagnosis. They should provide tools to clinicians to help prescribe promptly optimal treatments when necessary. Consequently, these tests should contribute to saving human lives, rationalizing treatment, reducing the development of antibiotic resistance and avoid unnecessary hospitalizations.

The invention relates to a kitchen garbage degrading composite microbial inoculum and a preparation method and application thereof. The kitchen garbage degrading composite microbial inoculum is prepared by mixing a mixed inoculum of bacillus amyloliquefaciens, radiation-resistant methylobacterium, dispersed pantoea, pseudomonas oryzihabitans, citrobacter freundii and staphylococcus cohnii and a carrier, wherein the mass of the mixed inoculum accounts for 15-25% of the total mass of the kitchen garbage-degrading composite microbial inoculum; the mass ratio of the bacillus amyloliquefaciens, the radiation-resistant methylobacterium, the dispersed pantoea, the pseudomonas oryzihabitans, the citrobacter freundii and the staphylococcus cohnii is (1.5-3):(1-1.5):(1-1.5): (1-1.5):(1-1.5):(1-1.5); the kitchen garbage-degrading composite microbial inoculum is used for degrading kitchen garbage. Compared with the prior art, the kitchen garbage degrading composite microbial inoculum has the advantages as follows: the kitchen garbage degrading composite microbial inoculum can effectively degrade common vegetables, grains, fish, poultry meat and other kitchen garbage, has the degradation rate being above 80%, is high in degradation speed rate and small in odor, does not produce pollutants or poisonous substances, and is low in cost and stable in performance.

This invention provides methods of treating patients having a Staphylococcus infection where the patient also has a low level of Pseudomonas aeruginosa. The methods comprise administering an antagonist of the Pseudomonas Type III Secretion System, e.g., an anti-PcrV antibody antagonist.

The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).

The present invention relates to DNA-based methods for universal bacterial detection, for specific detection of the common bacterial pathogens Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Staphylococcus saprophyticus, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis as well as for specific detection of commonly encountered and clinically relevant bacterial antibiotic resistance genes directly from clinical specimens or, alternatively, from a bacterial colony. The above bacterial species can account for as much as 80% of bacterial pathogens isolated in routine microbiology laboratories. The core of this invention consists primarily of the DNA sequences from all species-specific genomic DNA fragments selected by hybridization from genomic libraries or, alternatively, selected from data banks as well as any oligonucleotide sequences derived from these sequences which can be used as probes or amplification primers for PCR or any other nucleic acid amplification methods. This invention also includes DNA sequences from the selected clinically relevant antibiotic resistance genes. With these methods, bacteria can be detected (universal primers and/or probes) and identified (species-specific primers and/or probes) directly from the clinical specimens or from an isolated bacterial colony. Bacteria are further evaluated for their putative susceptibility to antibiotics by resistance gene detection (antibiotic resistance gene specific primers and/or probes). Diagnostic kits for the detection of the presence, for the bacterial identification of the above-mentioned bacterial species and for the detection of antibiotic resistance genes are also claimed. These kits for the rapid (one hour or less) and accurate diagnosis of bacterial infections and antibiotic resistance will gradually replace conventional methods currently used in clinical microbiology laboratories for routine diagnosis. They should provide tools to clinicians to help prescribe promptly optimal treatments when necessary. Consequently, these tests should contribute to saving human lives, rationalizing treatment, reducing the development of antibiotic resistance and avoid unnecessary hospitalizations.

This invention relates to the production of recombinant lysostaphin in a homogenous form through the use of recombinant DNA molecules that express homogenous lysostaphin and host cells transformed with these DNA molecules. This invention also relates to the production of truncated forms of lysostaphin. The resulting lysostaphin preparations can be administered to those at infected or risk for infection by staphylococcal bacteria.

The present invention provides Gyrase B and/or Topoisomerase IV par E inhibitors, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed by gram positive, gram negative and anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Pseudomonas spp., Acenetobacter spp., Moraxalla spp., Chlamydia spp., Mycoplasma spp., Legionella spp., Ktycobacterium spp., Helicobacter, Clostridium spp., Bacteroides spp., Corynebacterium, Bacillus spp., Enterobactericeae,’ (E. coli, Klebsiella spp., Proteus spp., etc.) or any combination thereof. Also provided, are processes for preparing compounds disclosed herein, pharmaceutical compositions containing compounds disclosed herein, and methods of treating bacterial infections. (Formula)

The invention relates to a method for detecting staphylococcus aureus, namely a method for enriching and screening the staphylococcus aureus by a one-step method. The method comprises the following steps of: utilizing a superparamagnetic nano particle covered by a staphylococcus aureus specific antibody to be specially combined with the staphylococcus aureus to form a composite; collecting a superparamagnetic nano particle composite under the attraction effect of an external magnetic field; inoculating the enriched composite into a culture medium to culture for 6-12 hours; and utilizing a staphylococcus aureu colloidal gold colloidal gold test paper to carry out qualitative and quantitative detection. The invention further provides the corresponding colloidal gold colloidal gold test paper for rapidly detecting the staphylococcus aureus, which has the flexibility of 104 cfu/mL of bacteria liquid and can be used for food safe detection, clinical rapid diagnosis, and onsite rapid screening of samples including water quality and the like.

The invention discloses staphylococcus pasteuri and application thereof in decolorization. The strain is staphylococcus pasteuri CGMCC No.3431. The staphylococcus pasteuri has broad-spectrum azo dye decolorizing capacity, can adapt to extreme environment and can still decolorize azo dye under the alkaline condition. The strain has the advantages of solving the problems existing in the prior art, improving the efficiency of the conventional wastewater treatment method and having industrial application prospect.

Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing HIa to provide immunoprotection against S. aureus pneumonia. In certain aspects the invention includes a HIa with reduced toxicity, represented by a recombinant mutant form of HIa (HlaH35L) in which histidine 35 is converted to leucine, which can be used to abrogate the productive assembly of the toxin and protect a subject from staphylococcal pneumonia.

The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including Staphylococcal origin. Ideally, the present invention is directed to a recombinant staphylococcal MSCRAMM or MSCRAMM-like proteins, or fragment thereof, with reduced binding to its host ligand, for use in therapy.

The invention discloses application of elsholtzia volatile oil in anti-bacteria and antibiotic resistant bacteria. The elsholtzia volatile oil is extracted by steam distillation. The elsholtzia volatile oil has certain functions of killing and/or inhibiting growth on bacteria of staphylococcus, escherichia coli, candida, pseudomonas, enterobacter, streptococcus and the like and fungi. The elsholtzia volatile oil has certain functions of killing and/or inhibiting growth on bacteria of drug-resistant staphylococcus, drug-resistant escherichia coli, drug-resistant enterobacter, drug-resistant klebsiella, drug-resistant pseudomonas, drug-resistant acinetobacter, drug-resistant streptococcus, and drug-resistant enterococcus and the like. The elsholtzia volatile oil can be used in industries offood, medicine, health care products, cosmetics and the like and can be used for preparing various forms of products with antibacterial and antibiotic resistant bacteria functions, and belongs to thenew application field of the elsholtzia volatile oil.

The invention discloses a method for reducing urea in the fermented grains of Luzhou-flavor liquor, belonging to the fields of microorganism production and utilization. In the invention, lactobacillus reuteri or crude enzyme liquid thereof is added before the fermented grains of liquor are added into a pit for fermentation, and the content of important precusor substance urea of EC in the fermented grains is reduced by 100% while basically no effect is realized without adding a bacterial strain or enzyme liquid or by adding staphylococcus saprophyticus or enzyme liquid thereof. In the invention, the adopted lactobacillus reuteri is food-grade safe bacteria, and other harmful substances are not generated after the lactobacillus reuteri is applied to the fermented grains. The method disclosed by the invention has good industrial application value.

The invention relates to a method for degradation of polychlorinated biphenyls by staphylococcus epidermidis. The method comprises the following steps: inoculating staphylococcus epidermidis in a polychlorinated biphenyl degradation culture medium and subjecting the staphylococcus epidermidis to the shaking culture at 28-32 DEG C for 24-120 hours; and analyzing the degradation effect of the bacterial strain on the PCBs after the culture is subjected to high performance liquid chromatograph determination. By the addition of extra carbon source glucose, the method can ensure that the staphylococcus epidermidis is more efficient in degrading the polychlorinated biphenyls, thereby allowing the bacteria to obtain the conditions for degrading the polychlorinated biphenyl.

A composition including arginine or a salt thereof, a zinc salt, preferably arginine bicarbonate and zinc carbonate (ABZC), in combination, plus one or more physiologically acceptable excipients, administered for the modification of cutaneous microfloras, generally to inhibit the growth of pathogenic Staphylococcus aureus bacteria and also promote the growth of non-pathogenic Staphylococcus epidermidis bacteria, and methods for using such composition.

The invention discloses a method for restoring arsenic-polluted soil by plant-microorganism combination. The method comprises the following steps of firstly, screening plants and microorganisms, so asto obtain plant clinopodium urticifolium with high arsenic resistance and microbial staphylococcus saprophyticus with high arsenic resistance; next, planting the plant clinopodium urticifolium with high arsenic resistance into heavy metal arsenic-polluted soil, and adding the arsenic-resistant microbial staphylococcus saprophyticus into the root soil of arsenic-enriched plant; and carrying out conventional culture, watering and moisturizing, wherein arsenic in the enriched soil is restored by utilizing the absorption effect of the arsenic-enriched plants on the arsenic and the strengthening effect of the arsenic-resistant microorganisms, and the aim of repairing the arsenic-polluted soil in a tail mining area can be achieved by repeating the above process. The soil restoring method is good in effect, low in cost and easy to manage and operate, no secondary pollution is generated, and the method has a wide application prospect.

RNAIII inhibiting peptide (RIP) has been established as an effective inhibitor of staphylococcal infections. Non-peptide small molecule analogs based on a pharmacophore conforming to the putative atomic structure of RIP, can be identified by computer screening of that pharmacophore against established libraries of known small molecules other than peptides. One such identified structural analog is hamamelitannin. When tested for effective inhibition of staphylococcal infections, hamamelitannin demonstrated inhibition similar to that exhibited by RIP. Other analogs can be identified and similarly used.

The present invention relates to a kind of chlorine tolerant microbe and its screening process. The chlorine tolerant microbe strain is Staphylococcus saprophyticus V430 in the preservation number of CCTCC No. M205145. The Staphylococcus saprophyticus V430 has circular opaque colony shape with lug and smooth edges; spherical single, paired or piled cells of d in 0.6-0.9 micron without flagellum; no motion, no endogeneous spore, gram positive and anaerobic property; and optimal growth pH value of 6.0-7.5 and temperature of 25-45 deg.c. It can survive in high chlorine ion concentration environment and degrade high concentration organic pollutant effectively.